Landscape of somatic mutations in 560 breast cancer whole-genome sequences

Journal: Nature

Published: 2016-05-02

DOI: 10.1038/nature17676

Affiliations: 50

Authors: 88

Go to article

Research Highlight

Detailed genetic picture of breast cancer revealed

© SEBASTIAN KAULITZKI/Science Photo Library

© SEBASTIAN KAULITZKI/Science Photo Library

An international team has uncovered the most detailed evidence yet that the genetic profiles of breast cancers are highly specific to each patient. This finding represents a step towards bespoke cancer treatment based on an individual’s cancer genome.

In a study published in Nature, researchers analysed the whole genomes of 560 breast tumours, identifying 93 mutated cancer genes that were implicated in the genesis of breast cancer, including five previously unknown genes. They also found that the tumors of women carrying the BRCA1 or BRCA2 genes were genetically distinct from each other and from other breast cancers.

The study’s authors note that this information could one day help direct doctors to the most effective treatment for cancer sufferers.

"In the future, we'd like to be able to profile individual cancer genomes so that we can identify the treatment most likely to be successful for a woman or man diagnosed with breast cancer. It is a step closer to personalized healthcare for cancer," said lead author Serena Nik-Zainal from the Wellcome Trust Sanger Institute in a statement.

The multi-centre team included researchers from The University of Texas MD Anderson Cancer Center.

Supported content

  1. Nature 2016; 534, 47–54. doi: 10.1038/nature17676
Institutions Share
Wellcome Sanger Institute, United Kingdom (UK) 0.30
Cancer GenomiCs.nl (CGC.nl), Netherlands 0.06
The University of Texas MD Anderson Cancer Center, United States of America (USA) 0.03
Lund University (LU), Sweden 0.03
Hanyang University (HYU), South Korea 0.03
University of Antwerp (UA), Belgium 0.03
Netherlands Cancer Institute (NKI), Netherlands 0.03
University of Oslo (UiO), Norway 0.03
Institute Jules Bordet, ULB, Belgium 0.02
Radboud University Nijmegen (RU), Netherlands 0.02
Asan Medical Center (AMC), South Korea 0.02
Academic Medical Center (AMC), UvA, Netherlands 0.02
University of Iceland, Iceland 0.02
Centre Léon Bérard (CLB), France 0.02
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.02
Brigham and Women's Hospital (BWH), United States of America (USA) 0.02
Synergie Lyon Cancer, France 0.02
Oslo University Hospital (OUS), Norway 0.02
Ninewells Hospital and Medical School, United Kingdom (UK) 0.02
The University of Queensland (UQ), Australia 0.02
IRCCS National Cancer Institute (INT) Bari, Italy 0.01
GZA Hospitals, Belgium 0.01
UNICANCER Group, France 0.01
French National Cancer Institute (INCa), France 0.01
Host-Graft-Tumor Interaction, Cell and Gene Engineering, France 0.01
Radboud University Medical Centre (Radboudumc), RU, Netherlands 0.01
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA) 0.01
Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, United Kingdom (UK) 0.01
Gachon University Gil Medical Center, South Korea 0.01
European Bioinformatics Institute (EMBL-EBI), United Kingdom (UK) 0.01
Wellcome Trust Genome Campus, United Kingdom (UK) 0.01
Department of Genetics and Developmental Biology, France 0.01
Associate Directorate for Theory, Simulation, and Computation (ADTSC), LANL, United States of America (USA) 0.01
King's College London (KCL), United Kingdom (UK) 0.01
The Institute of Cancer Research (ICR), United Kingdom (UK) 0.01
University of Bergen (UIB), Norway 0.01
Haukeland University Hospital, Norway 0.01
National Cancer Centre Singapore (NCCS), Singapore 0.01
Singapore General Hospital (SGH), Singapore 0.01
INRIA Grenoble - Rhône-Alpes Research Centre, France 0.01
Biomedical Sciences Group, KU Leuven, Belgium 0.01
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK) 0.01
Royal Brisbane and Women's Hospital (RBWH), Australia 0
Queensland Health, Australia 0

Return